DK2606128T3 - Permanent human amniocytcellelinje til fremstilling af influenzavirus - Google Patents
Permanent human amniocytcellelinje til fremstilling af influenzavirus Download PDFInfo
- Publication number
- DK2606128T3 DK2606128T3 DK11781731.2T DK11781731T DK2606128T3 DK 2606128 T3 DK2606128 T3 DK 2606128T3 DK 11781731 T DK11781731 T DK 11781731T DK 2606128 T3 DK2606128 T3 DK 2606128T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- influenza virus
- cell
- virus
- medium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (11)
1. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine, hvilken fremgangsmåde omfatter a) inficering af en permanent human amniocytcelle med et influenzavirus, b) dyrkning af den permanente humane amniocytcelle, c) ekspression af influenzavirusset og d) isolering af influenzavirusset fra mediet, hvor den permanente humane amniocytcelle udtrykker de adenovirale genprodukter E1A og E1B.
2. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge krav 1, hvor den permanente humane amniocytcelle på tidspunktet for inficeringen med influenzavirusset befinder sig i eller mellem den eksponentielle vækstfase og den stationære vækstfase.
3. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge krav 1, hvor isoleringen af influenzavirusset fra mediet i trin d) sker ved hjælp af densitetsgra-dient-differential- eller -zonecentrifugering.
4. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge krav 1, hvor de adenovirale genprodukter E1A og E1B omfatter nukleotiderne 1 til 4344, 505 til 3522 eller nukleotiderne 505 til 4079 af det humane adenovirus serotype-5.
5. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge et hvilket som helst af de foregående krav, hvor den permanente humane amniocytcelle udtrykker det adenovirale genprodukt pIX.
6. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge et hvilket som helst af de foregående krav, hvor der før inficeringen med et influenzavirus sker et fuldstændigt medieskift eller en 1:2-fortynding med medium.
7. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge et hvilket som helst af de foregående krav, hvor der ved inficeringen med et influenzavirus tilsættes en trypsinkoncentration på 1 x 10'4 U/celle, 1 x 10'5 U/celle, 3 x 10'5 U/celle, 5 x 10'5 U/celle eller 1 x 10'6 U/celle.
8. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge et hvilket som helst af de foregående krav, hvor der ved inficeringen med et influenzavirus anvendes en virusmængde angivet som MOI-værdi i området fra 0,001 til 0,3.
9. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge et hvilket som helst af de foregående krav, hvor influenzavirusset er et humant influenzavirus, et hesteinfluenzavirus eller et svineinfluenzavirus.
10. Fremgangsmåde til fremstilling af en influenzavirusbaseret vaccine ifølge et hvilket som helst af de foregående krav, hvor influenzavirusset er valgt blandt influenzavirusstammerne A/PR/8/34, A/Uruguay/716/2007, A/Brisbane/59/2007, B/Florida/4/2006, svineinfluenza (A/Swine (H1N2) Bakum/1832/00) eller hesteinfluenza (A/Equine, A/Newmarket/1/93 (H3N8)).
11. Anvendelse af en permanent human amniocytcelle til fremstilling af en influenzavirusbaseret vaccine, hvor den permanente humane amniocytcelle udtrykker de adeno-virale genprodukter E1A og E1B.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010037008 | 2010-08-16 | ||
| DE102011050353 | 2011-05-13 | ||
| PCT/DE2011/075194 WO2012041311A1 (de) | 2010-08-16 | 2011-08-16 | Permanente humane amniozyten zelllinie zur herstellung von influenzaviren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2606128T3 true DK2606128T3 (da) | 2014-12-01 |
Family
ID=44936126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11781731.2T DK2606128T3 (da) | 2010-08-16 | 2011-08-16 | Permanent human amniocytcellelinje til fremstilling af influenzavirus |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20130344569A1 (da) |
| EP (1) | EP2606128B1 (da) |
| JP (1) | JP5928843B2 (da) |
| KR (1) | KR101780257B1 (da) |
| CN (1) | CN103168100B (da) |
| AU (1) | AU2011307655B2 (da) |
| BR (1) | BR112013003766B1 (da) |
| CA (1) | CA2808453C (da) |
| DE (1) | DE112011102737A5 (da) |
| DK (1) | DK2606128T3 (da) |
| ES (1) | ES2524894T3 (da) |
| IL (1) | IL224728A (da) |
| MX (1) | MX337687B (da) |
| PL (1) | PL2606128T3 (da) |
| PT (1) | PT2606128E (da) |
| RU (1) | RU2565546C2 (da) |
| SG (1) | SG187863A1 (da) |
| TW (1) | TW201211257A (da) |
| WO (1) | WO2012041311A1 (da) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| AU2005322353B2 (en) * | 2004-12-23 | 2011-09-01 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
| EP2614836A3 (en) * | 2005-10-17 | 2013-10-23 | MedImmune, LLC | High growth reassortant influenza A virus |
| DE102005054628A1 (de) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| RU2487935C2 (ru) * | 2006-09-15 | 2013-07-20 | Медиммун, Ллк. | Линии клеток почки собаки майдин-дэрби (mdck), поддерживающие рост вирусов до высоких титров, и способ применения этих клеток в биореакторе |
-
2011
- 2011-08-16 SG SG2013011499A patent/SG187863A1/en unknown
- 2011-08-16 US US13/816,976 patent/US20130344569A1/en not_active Abandoned
- 2011-08-16 MX MX2013001772A patent/MX337687B/es active IP Right Grant
- 2011-08-16 RU RU2013110786/10A patent/RU2565546C2/ru active IP Right Revival
- 2011-08-16 DK DK11781731.2T patent/DK2606128T3/da active
- 2011-08-16 JP JP2013524350A patent/JP5928843B2/ja active Active
- 2011-08-16 PL PL11781731T patent/PL2606128T3/pl unknown
- 2011-08-16 WO PCT/DE2011/075194 patent/WO2012041311A1/de active Application Filing
- 2011-08-16 EP EP11781731.2A patent/EP2606128B1/de active Active
- 2011-08-16 ES ES11781731.2T patent/ES2524894T3/es active Active
- 2011-08-16 KR KR1020137006640A patent/KR101780257B1/ko active IP Right Grant
- 2011-08-16 CA CA2808453A patent/CA2808453C/en active Active
- 2011-08-16 PT PT117817312T patent/PT2606128E/pt unknown
- 2011-08-16 TW TW100129162A patent/TW201211257A/zh unknown
- 2011-08-16 DE DE112011102737T patent/DE112011102737A5/de not_active Withdrawn
- 2011-08-16 AU AU2011307655A patent/AU2011307655B2/en active Active
- 2011-08-16 CN CN201180050018.7A patent/CN103168100B/zh active Active
- 2011-08-16 BR BR112013003766-0A patent/BR112013003766B1/pt active IP Right Grant
-
2013
- 2013-02-14 IL IL224728A patent/IL224728A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2565546C2 (ru) | 2015-10-20 |
| EP2606128B1 (de) | 2014-09-10 |
| MX337687B (es) | 2016-03-15 |
| SG187863A1 (en) | 2013-03-28 |
| KR20130097191A (ko) | 2013-09-02 |
| IL224728A (en) | 2016-05-31 |
| CA2808453A1 (en) | 2012-04-05 |
| KR101780257B1 (ko) | 2017-09-21 |
| CN103168100B (zh) | 2016-04-13 |
| PT2606128E (pt) | 2014-12-09 |
| WO2012041311A1 (de) | 2012-04-05 |
| TW201211257A (en) | 2012-03-16 |
| CA2808453C (en) | 2020-05-05 |
| EP2606128A1 (de) | 2013-06-26 |
| US20130344569A1 (en) | 2013-12-26 |
| JP2013537543A (ja) | 2013-10-03 |
| ES2524894T3 (es) | 2014-12-15 |
| RU2013110786A (ru) | 2014-09-27 |
| BR112013003766B1 (pt) | 2021-08-24 |
| CN103168100A (zh) | 2013-06-19 |
| BR112013003766A2 (pt) | 2016-05-31 |
| PL2606128T3 (pl) | 2015-02-27 |
| AU2011307655A1 (en) | 2013-03-21 |
| MX2013001772A (es) | 2013-06-03 |
| AU2011307655B2 (en) | 2015-12-17 |
| DE112011102737A5 (de) | 2013-06-06 |
| JP5928843B2 (ja) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10329536B2 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture | |
| AU2002338666B2 (en) | Multiplication of viruses in a cell culture | |
| US7504248B2 (en) | Production of viruses viral isolates and vaccines | |
| JP2004331673A (ja) | インフルエンザウイルスの複製のための動物細胞および方法 | |
| Liu et al. | Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture | |
| CN104812894B (zh) | 新型mva病毒及其用途 | |
| EP3039127B1 (en) | Large scale production of viruses in cell culture | |
| CA2750055A1 (en) | Method for purifying viruses using a density gradient | |
| DK2606128T3 (da) | Permanent human amniocytcellelinje til fremstilling af influenzavirus | |
| US8716016B2 (en) | Immortal avian cell line and methods of use | |
| WO2010046335A1 (en) | Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions | |
| Vázquez Ramírez | Process intensification for the production of MVA and influenza A virus in high density suspension cultures of AGE1. CR. pIX cells | |
| WO2024188803A1 (en) | Production of poxviruses from quail cell cultures | |
| WO2024188802A1 (en) | Methods of isolating poxviruses from avian cell cultures |